2017 Fiscal Year Final Research Report
Inhibition of PAI-1 limits chemotherapy resistance of lung cancer through suppressing myofibroblasts characteristic of cancer-associated fibroblasts.
| Project/Area Number |
15K19419
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Namba Masashi
Nakashima Taku
Hattori Noboru
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 肺癌 / 癌関連線維芽細胞 / PAI-1 / 筋線維芽細胞 / 化学療法 |
|---|
| Outline of Final Research Achievements |
Plasminogen activator inhibitor-1 (PAI-1) is associated with the differentiation of fibroblast into myofibroblasts (MF). Fibroblasts in the tumor stroma are called cancer-associated fibroblasts (CAFs). CAFs with MF phenotype promote chemotherapy resistance. Here, we investigated whether inhibition of PAI-1 suppresses the MF phenotype of CAFs and results in increased chemosensitivity in lung cancer. We found that PAI-1 inhibition in CAFs co-cultured with lung cancer cells increased the effects of chemotherapy. Our data suggest that inhibition of PAI-1 increases the chemosensitivity of lung cancer cells by suppressing the MF phenotype of CAFs. Hence, PAI-1 might be a promising therapeutic target for patients with chemoresistant lung cancer with CAFs.
|
| Free Research Field |
肺癌
|
